Reactive versus neoplastic bone marrow: Problems and pitfalls

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 4, 2008, Pages 587-594

  Hasserjian, Robert P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARAPROTEIN; RETICULIN;

ANEMIA; BONE MARROW BIOPSY; BONE MARROW CANCER; CANCER GRADING; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; PANCYTOPENIA; REVIEW; THROMBOCYTOPENIA;

BIOPSY; BONE MARROW; BONE MARROW DISEASES; BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; HUMANS; PATHOLOGY;

EID: 41749089146     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Naresh KN, Lampert I, Hasserjian R, et al. Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol. J Clin Pathol. 2006;59:903-911.
2. Bonds LA, Barnes P, Foucar K, Sever CE. Acetic acid-zinc-formalin: a safe alternative to B-5 fixative. Am J Clin Pathol. 2005;124:205-211.
3. Mullink H, Henzen-Logmans SC, Tadema TM, Mol JJ, Meijer CJ. Influence of fixation and decalcification on the immunohistochemical staining of cell-specific markers in paraffin-embedded human bone biopsies. J Histochem Cytochem. 1985;33:1103-1109.
4. Wickham CL, Sarsfield P, Joyner MV, Jones DB, Ellard S, Wilkins B. Formic acid decalcification of bone marrow trephines degrades DNA: alternative use of EDTA allows the amplification and sequencing of relatively long PCR products. Mol Pathol. 2000;53:336.
5. Brown RS, Edwards J, Bartlett JW, Jones C, Dogan A. Routine acid decalcification of bone marrow samples can preserve DNA for FISH and CGH studies in metastatic prostate cancer. J Histochem Cytochem. 2002;50:113-115.
6. DePalma L. The effect of decalcification and choice of fixative on histiocytic iron in bone marrow core biopsies. Biotech Histochem. 1996;71:57-60.
7. Bauermeister DE. Quantitation of bone marrow reticulin - a normal range. Am J Clin Pathol. 1971;56:24-31.
8. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90:1128-1132.
9. Wickramasinghe SN, Bain BJ. Pathology of the marrow: general considerations. In: Wickramasinghe SN, McCullogh J, eds. Blood and Bone Marrow Pathology. London, England: Elsevier Science Limited; 2003:87-128.
10. Krause JR. The bone marrow in nutritional deficiencies. Hematol Oncol Clin North Am. 1988;2:557-566.
11. Fenaux P. Chromosome and molecular abnormalities in myelodysplasia syndromes. Int J Hematol. 2001;73:429-437.
12. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol. 2005;124:170-181.
13. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplasia syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood. 2003;102:394-403.
14. Hasserjian RP, Pinkus GS. DBA.44: an effective marker for detetion of hairy cell leukemia in bone marrow biopsies. Appl Immunohistochem. 1994;2:197-204.
15. Pittaluga S, Verhoef G, Maes A, Boogaerts MA, De Wolf-Peeters C. Bone marrow trephines: findings in patients with hairy cell leukaemia before and after treatment. Histopathology. 1994;25:129-135.
16. Castello A, Coci A, Magrini U. Paraneoplastic marrow alterations in patients with cancer. Haematologica. 1992;77:392-397.
17. Kwong YL, Lee CP, Chan TK, Chan LC. Flow cytometric measurement of glycosylphosphatidyl-inositol-linked surface proteins on blood cells of patients with paroxysmal nocturnal hemoglobinuria. Am J Clin Pathol. 1994;102:30-35.
18. Chang KL, Gaal KK, Huang Q, Weiss LM. Histiocytic lesions involving the bone marrow. Semin Diagn Pathol. 2003;20:226-236.
19. Sills RH. Indications for bone marrow examination. Pediatr Rev. 1995;16:226-228.
20. McKenna RW. Myelodysplasia and myeloproliferative disorders in children. Am J Clin Pathol. 2004;122(suppl):S58-S69.
21. Sashida G, Takaku TI, Shoji N, et al. Clinico-hematologic features of myelodysplasia syndrome presenting as isolated thrombocytopenia: an entity with a relatively favorable prognosis. Leuk Lymphoma. 2003;44:653-658.
22. Gupta R, Johari V, Hasserjian R. Myelodysplasic syndrome with isolated del(20q): a distinct clinicopathologic entity? Mod Pathol. 2006;19:229A.
23. Katsumata Y, Suzuki T, Kuwana M, et al. Anti-c-Mpl (thrombopoietin receptor) autoantibody-induced amegakaryocytic thrombocytopenia in a patient with systemic sclerosis. Arthritis Rheum. 2003;48:1647-1651.
24. Evans RH, Scadden DT. Haematological aspects of HIV infection. Baillieres Best Pract Res Clin Haematol. 2000;13:215-230.
25. Thiele J, Zirbes TK, Bertsch HP, Titius BR, Lorenzen J, Fischer R. AIDS-related bone marrow lesions - myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Anal Cell Pathol. 1996;11:141-157.
26. Karcher DS, Frost AR. The bone marrow in human immunodeficiency virus (HIV)-related disease: morphology and clinical correlation. Am J Clin Pathol. 1991;95:63-71.
27. Diebold J, Molina T, Camilleri-Broet S, Le Tourneau A, Audouin J. Bone marrow manifestations of infections and systemic diseases observed in bone marrow trephine biopsy review. Histopathology. 2000;37:199-211.
28. Ng MH, Li EK, Feng CS. Gelatinous transformation of bone marrow in systemic lupus erythematosus. J Rheumatol. 1989;16:989-992.
29. Paquette RL, Meshkinpour A, Rosen PJ. Autoimmune myelofibrosis: a steroid-responsive cause of bone marrow fibrosis associated with systemic lupus erythematosus. Medicine (Baltimore). 1994;73:145-152.
30. Brunning RD, McKenna RW. Lesions simulating lymphomas. In: Tumors of the Bone Marrow. Washington, DC: Armed Forces Institute of Pathology; 1994: 409-455. Atlas of Tumor Pathology; 3rd series, fascicle 9.
31. Thiele J, Kvasnicka HM, Orazi A. Bone marrow histopathology in myeloproliferative disorders - current diagnostic approach. Semin Hematol. 2005;42:184-195.
32. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
33. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
34. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
35. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
36. Vardiman JW, Imber M, Pierre R, Brunning RD, Thiele J, Flandrin G. Chronic myelogenous leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:20-26. World Health Organization Classification of Tumours.
37. Kimura A, Katoh O, Hyodo H, Kuramoto A, Satow Y. Platelet derived growth factor expression, myelofibrosis and chronic myelogenous leukemia. Leuk Lymphoma. 1995;18:237-242.
38. Rywlin AM, Ortega RS, Dominguez CJ. Lymphoid nodules of bone marrow: normal and abnormal. Blood. 1974;43:389-400.
39. Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica. 2006;91:972-975.
40. Thiry A, Delvenne P, Fontaine MA, Boniver J. Comparison of bone marrow sections, smears and immunohistological staining for immunoglobulin light chains in the diagnosis of benign and malignant plasma cell proliferations. Histopathology. 1993;22:423-428.
41. Kass L, Kapadia IH. Perivascular plasmacytosis: a light-microscopic and immunohistochemical study of 93 bone marrow biopsies. Acta Haematol. 2001; 105:57-63.
42. Grogan TM, Camp BV, Kyle RA, Muller-Hermelink HK, Harris NL. Plasma cell neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:142-156. World Health Organization Classification of Tumours.
43. Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol. 2005;29:1549-1557.
44. Swan N, Skinner M, O'Hara CJ. Bone marrow core biopsy specimens in AL (primary) amyloidosis: a morphologic and immunohistochemical study of 100 cases. Am J Clin Pathol. 2003;120:610-616.
45. Hasserjian RP, Goodman HJ, Lachmann HJ, Muzikansky A, Hawkins PN. Bone marrow findings correlate with clinical outcome in systemic AL amyloidosis patients. Histopathology. 2007;50:567-573.